Quick Facts / Company Snapshot
| Metric | Detail |
| Company Name | 10x Genomics, Inc. |
| Ticker Symbol | Nasdaq: TXG |
| Headquarters | Pleasanton, California |
| Year Ended | December 31, 2025 |
| Total Revenue (2025) | $642,823,000 |
| Gross Profit (2025) | $443,881,000 |
| Net Loss (2025) | $(43,544,000) |
| Total Assets (2025) | $1,041,365,000 |
| Total Equity (2025) | $796,326,000 |
| Cash & Cash Equivalents (2025) | $473,966,000 |
| R&D Expense (2025) | $238,632,000 |
| Consumables Revenue (2025) | $526,028,000 |
| Instruments Revenue (2025) | $38,367,000 |
| Instruments Sold (2025) | 1,007 |
| Cumulative Instruments Sold | 8,046 |
| Consumable Reactions Sold (2025) | 424,000 |
| Commercial Team Size | 473 employees |
| CEO | Serge Saxonov |
| CFO | Adam S. Taich |
| Class A Shares Outstanding | 117,673,382 |
Company Overview
10x Genomics, Inc. is a leading life sciences technology firm built around a singular, ambitious mission: to accelerate the mastery of biology in order to advance human health. To achieve this, the organization designs and develops highly sophisticated products and solutions aimed at interrogating biological systems at a resolution and scale that matches the profound complexity of biology itself.
- Global reach: The enterprise sells its solutions in over 50 countries worldwide.
- Scientific validation: Over 10,000 peer-reviewed articles have been published using data generated by the company’s platforms.
- Customer base: Core buyers include academic researchers, government institutions, translational researchers, biopharmaceutical companies, and biotechnology firms.
The corporate architecture relies on an integrated research solution encompassing advanced instruments, specially engineered consumables, and powerful proprietary software. This multifaceted approach requires deep, cross-disciplinary expertise spanning chemistry, molecular biology, microfluidics, hardware, computational biology, and software engineering. By combining these distinct disciplines, the enterprise allows its customers to understand biology at multiple dimensions—ranging from the individual single cell to the spatial distribution of cells across entire tissues.
Business Segments
10x Genomics operates through a highly focused revenue structure consisting of two distinct primary segments: Products and Services, and License and Royalty revenue.
Products and Services
The Products and Services segment is the core operational engine of the enterprise, functioning as the primary driver of top-line growth. This segment directly monetizes the company’s integrated technology ecosystems.
- Total Revenue: $596,688,000 in 2025.
- Percentage of Total Revenue: 92.8% (Calculated from $596.7M / $642.8M).
- Revenue streams: Instrument sales, consumable sales, and extended warranty service agreements.
This segment provides end-to-end capabilities for scientists. Customers purchase instruments to form the foundational hardware infrastructure in their laboratories. Following the capital expenditure on hardware, customers continuously purchase proprietary consumables required to run specific biological assays. Furthermore, to protect their investments, researchers acquire extended warranty service agreements that guarantee continued operational uptime.
License and Royalty Revenue
The License and Royalty segment monetizes the company’s robust and extensively enforced intellectual property portfolio.
- Total Revenue: $46,135,000 in 2025.
- Percentage of Total Revenue: 7.2% (Calculated from $46.1M / $642.8M).
- Revenue drivers: Strategic settlements, licensing fees, and ongoing royalty streams.
This segment saw dramatic growth in 2025 due to the successful resolution of complex worldwide patent litigation. By securing settlements that require competing entities to pay upfront licensing fees and recurring royalties, the company converts its extensive research and development investments into high-margin licensing income.
History and Evolution
Since the launch of its very first product in mid-2015, the enterprise has rapidly transformed from an early-stage innovator into an established leader within the global life sciences research tools market. This swift evolution was fueled by a relentless commitment to expanding the frontiers of genomic and spatial analysis.
- Installed base explosion: From inception through December 31, 2025, the business has successfully placed 8,046 total instruments globally.
- Scale Bio Acquisition: In August 2025, the business acquired Scale Biosciences, Inc., executing a $9.2 million cash and $13.5 million equity transaction to integrate new single-cell technology.
- IP Enforcement: 2025 marked a pivotal year for intellectual property protection, featuring major settlements with Vizgen and Bruker, solidifying the firm’s technological moat.
The technological progression of the company has continually shifted toward higher resolution and broader scale. The company expanded beyond its foundational single-cell capabilities (the Chromium platform) to aggressively pursue the spatial biology market by developing and launching the Visium and Xenium platforms. This evolution showcases a strategic pivot from merely counting and identifying cells in suspension to actually mapping where those cells reside in complex tissues—a breakthrough with massive implications for oncology and neuroscience.
Products and Services
The company divides its commercial offerings into three precise categories: Consumables, Instruments, and Services. Each plays a specific role in the overarching “razor-and-blade” commercial strategy.
Consumables
Consumables represent the recurring revenue engine of the business. Once a laboratory installs an instrument, it must repeatedly purchase the necessary chemical and biological reagents to run its experiments.
- Revenue: $526,028,000 in 2025.
- Percentage of Total Revenue: 81.8% (Calculated from $526.0M / $642.8M).
- Volume: 424,000 consumable reactions sold in 2025.
The consumables portfolio contains proprietary microfluidic chips, sophisticated slides, chemical reagents, and uniquely barcoded gel beads. These components act as the biological interface where scientific samples are partitioned, barcoded, and prepared for sequencing. In 2025, the company also integrated the QuantumScale Single Cell RNA and Methylation kits, obtained via the Scale Bio acquisition, into its consumables lineup.
Instruments
Instruments are the capital equipment foundation of the ecosystem. They are precisely engineered mechanical, fluidic, and optical devices designed to automate highly complex biological assays.
- Revenue: $38,367,000 in 2025.
- Percentage of Total Revenue: 6.0% (Calculated from $38.4M / $642.8M).
- Volume: 1,007 instruments sold in 2025.
The instrument fleet includes the Chromium X Series, the Visium CytAssist, and the Xenium Analyzer. These machines act as highly controlled delivery systems. For instance, the Chromium instrument partitions biological samples into over a million individual components, while the Xenium Analyzer utilizes advanced microscopy and optical signatures to identify RNA directly within tissue.
Services
The services category focuses on maximizing the operational lifespan and reliability of the hardware fleet.
- Revenue: $32,293,000 in 2025.
- Percentage of Total Revenue: 5.0% (Calculated from $32.3M / $642.8M).
- Growth: Increased 35% year-over-year in 2025.
Service revenue is generated largely through extended warranty agreements purchased by laboratories after the standard one-year warranty expires. These agreements ensure that the complex optics, fluidics, and robotics inside the instruments remain calibrated and functional, thereby protecting the customer’s capital investment and ensuring data integrity.
Brand Portfolio
The company’s brand portfolio is segmented into two overarching scientific methodologies: Single Cell (Chromium) and Spatial Biology (Visium and Xenium).
Chromium (Single Cell Platform)
Chromium is the company’s foundational technology platform, enabling the high-throughput analysis of individual biological cells.
- Cumulative Placements: 6,477 instruments sold.
- Total Revenue Contribution (Single Cell): $385.9 million in 2025.
- Percentage of Total Revenue: 60.0% (Calculated from $385.9M / $642.8M).
The Chromium system uses proprietary gel beads bearing unique barcodes to tag the contents of individual cells. The platform supports multiple assays, including Universal (3′ and 5′ gene expression), Flex (capable of handling fixed and formalin-fixed paraffin-embedded or FFPE tissues), and Epi (chromatin accessibility). It boasts high cell recovery rates and allows researchers to measure millions of single cells across experiments.
Visium (Spatial Platform)
Visium brings together the traditional worlds of histology (tissue study) and genomics.
- Cumulative Placements: 1,015 Visium CytAssist instruments sold.
- Platform Function: Identifies where biological components are physically located within tissue.
By utilizing high-density DNA arrays, Visium encodes the physical location of biological analytes. The Visium CytAssist instrument simplifies this workflow by transferring transcriptomic analytes from standard glass slides onto specially barcoded Visium slides. It supports HD WT Panel Gene Expression and HD 3′ Gene Expression assays, providing a visual map of analytes layered over tissue morphology images.
Xenium (In Situ Platform)
Xenium is the company’s pinnacle platform for targeted, subcellular spatial exploration.
- Cumulative Placements: 554 instruments sold.
- Total Revenue Contribution (Spatial overall): $210.8 million in 2025.
- Percentage of Total Revenue: 32.8% (Calculated from $210.8M / $642.8M).
The Xenium Analyzer allows scientists to detect hundreds or thousands of specific RNA targets directly in fresh frozen or FFPE tissue sections without needing conventional sequencing. It employs circularizable probes and fluorescent hybridization. The machine captures microscope images across successive rounds of hybridization to map the exact subcellular location of gene expression. It supports both pre-designed panels (up to 5,000 genes) and fully customizable gene subsets.
Geographical Presence
The organization manages a highly globalized footprint, shipping products to researchers in more than 50 countries. Sales are driven through a direct sales force in North America and select European regions, supplemented by third-party distributors across Asia, Oceania, South America, the Middle East, and Africa.
Americas
The Americas represent the largest, most mature market for the enterprise, heavily anchored by the United States.
- Total Revenue: $358,773,000 in 2025.
- Percentage of Total Revenue: 55.8% (Calculated from $358.7M / $642.8M).
- United States Revenue: $346,512,000.
The United States commands the vast majority of sales in this region, driven by immense academic institutions and deep-pocketed biopharmaceutical companies. The firm’s global headquarters, comprehensive research and development laboratories, and major manufacturing centers are deeply rooted in Pleasanton, California, facilitating rapid deployment across North America.
Europe, Middle East, and Africa (EMEA)
The EMEA region acts as the second-largest geographic revenue engine.
- Total Revenue: $161,716,000 in 2025.
- Percentage of Total Revenue: 25.2% (Calculated from $161.7M / $642.8M).
- Key Market: Germany is highlighted as one of the largest single markets outside North America.
Growth in the EMEA region is managed via a hybrid commercial model, utilizing direct sales forces in certain key European territories while relying on robust third-party distribution networks across the broader Middle East and Africa.
Asia-Pacific
The Asia-Pacific region is a critical strategic growth vector, albeit one that introduces distinct geopolitical complexities.
- Total Revenue: $122,334,000 in 2025.
- Percentage of Total Revenue: 19.0% (Calculated from $122.3M / $642.8M).
- China Revenue: $70,264,000.
China serves as the anchor market within this geographic footprint, generating the majority of the region’s top-line performance. To secure its supply chain and fulfill regional demand effectively, the company operates critical manufacturing and distribution centers in Singapore, alongside specialized manufacturing operations based in Taiwan.
Profit and Loss
The following table presents the enterprise’s consolidated statements of operations, capturing the financial performance across the past three years.
| Metric | 2025 ($ in thousands) | 2024 ($ in thousands) | 2023 ($ in thousands) |
| Products and services revenue | 596,688 | 610,464 | 618,727 |
| License and royalty revenue | 46,135 | 321 | — |
| Total Revenue | 642,823 | 610,785 | 618,727 |
| Cost of products and services revenue | 198,942 | 196,303 | 209,414 |
| Gross profit | 443,881 | 414,482 | 409,313 |
| Research and development expenses | 238,632 | 264,698 | 270,332 |
| Selling, general and administrative expenses | 316,134 | 344,343 | 343,330 |
| Gain on settlement | (49,900) | — | — |
| In-process research and development | — | — | 60,980 |
| Total operating expenses | 504,866 | 609,041 | 674,642 |
| Loss from operations | (60,985) | (194,559) | (265,329) |
| Interest income | 20,048 | 18,930 | 16,885 |
| Interest expense | — | (4) | (33) |
| Other income (expense), net | 1,030 | (2,067) | (286) |
| Loss before provision for income taxes | (39,907) | (177,700) | (248,763) |
| Provision for income taxes | 3,637 | 4,927 | 6,336 |
| Net loss | (43,544) | (182,627) | (255,099) |
Balance Sheet
The corporate balance sheet outlines the firm’s robust liquidity position and overall asset base as of the fiscal years ending 2025 and 2024.
| Metric | 2025 ($ in thousands) | 2024 ($ in thousands) |
| Cash and cash equivalents | 473,966 | 344,067 |
| Marketable securities | 49,443 | 49,335 |
| Accounts receivable, net | 47,013 | 87,862 |
| Inventory | 56,341 | 83,107 |
| Other receivables | 35,480 | 606 |
| Prepaid expenses and other current assets | 22,208 | 19,410 |
| Total current assets | 684,451 | 584,387 |
| Property and equipment, net | 226,711 | 252,648 |
| Operating lease right-of-use assets | 60,450 | 57,290 |
| Goodwill | 4,511 | 4,511 |
| Intangible assets, net | 62,329 | 15,671 |
| Other noncurrent assets | 2,913 | 4,129 |
| Total assets | 1,041,365 | 918,636 |
| Accounts payable | 12,733 | 12,909 |
| Accrued compensation and related benefits | 42,500 | 33,615 |
| Accrued expenses and other current liabilities | 39,971 | 41,165 |
| Deferred revenue (current) | 23,902 | 20,658 |
| Operating lease liabilities (current) | 10,985 | 9,286 |
| Contingent consideration (current) | 23,363 | — |
| Total current liabilities | 153,454 | 117,633 |
| Contingent consideration, noncurrent | 1,237 | — |
| Operating lease liabilities, noncurrent | 76,013 | 74,402 |
| Deferred revenue, noncurrent | 10,488 | 12,513 |
| Other noncurrent liabilities | 3,847 | 3,954 |
| Total stockholders’ equity | 796,326 | 710,134 |
| Total liabilities and stockholders’ equity | 1,041,365 | 918,636 |
Cash Flow
This section details the actual cash generation and expenditure behaviors of the company across operating, investing, and financing parameters.
| Metric | 2025 ($ in thousands) | 2024 ($ in thousands) | 2023 ($ in thousands) |
| Net loss | (43,544) | (182,627) | (255,099) |
| Stock-based compensation expense | 109,118 | 140,749 | 166,950 |
| Depreciation and amortization | 36,199 | 35,879 | 35,512 |
| Net cash provided by (used in) operating activities | 136,050 | 6,664 | (15,197) |
| Proceeds from maturities of marketable securities | 125,200 | 25,782 | 82,825 |
| Purchase of marketable securities | (123,435) | (48,876) | — |
| Asset acquisition, net | (9,268) | — | — |
| Purchases of property and equipment | (5,935) | (12,393) | (48,601) |
| Net cash (used in) provided by investing activities | (13,438) | (32,631) | 133,492 |
| Issuance of common stock from exercise of options/ESPP | 6,803 | 10,914 | 19,483 |
| Net cash provided by financing activities | 6,803 | 10,914 | 13,669 |
| Effect of exchange rate changes on cash | 484 | (164) | (33) |
| Net increase (decrease) in cash and cash equivalents | 129,899 | (15,217) | 131,931 |
| Cash and cash equivalents at end of year | 473,966 | 344,067 | 359,284 |
Board of Directors and Leadership Team
The company’s leadership structure relies heavily on scientists and industry veterans who directly govern the firm’s strategic and financial operations.
- Serge Saxonov: Serves as the Chief Executive Officer and sits on the Board of Directors. He operates as the Principal Executive Officer, guiding the overarching scientific and commercial vision of the enterprise.
- Adam S. Taich: Operates as the Chief Financial Officer. He acts as the Principal Financial and Accounting Officer, overseeing the company’s financial reporting, liquidity management, and accounting control systems.
- Eric S. Whitaker: Highlighted as a key executive officer responsible for critical operational parameters.
- Sarah Teichmann: An established member of the Board of Directors, ensuring high-level corporate governance and scientific oversight.
Subsidiaries, Associates, Joint Ventures
The corporate structure actively leverages targeted acquisitions to absorb new technologies and accelerate time-to-market for innovative platforms.
Scale Biosciences, Inc. (Scale Bio)
In August 2025, the company successfully acquired 100% of the outstanding shares of Scale Bio.
- Financial Terms: The initial transaction included a $9.2 million cash outlay combined with $13.5 million via the issuance of 1,099,992 shares of Class A common stock.
- Future Obligations: The deal structure includes up to $30.0 million in contingent consideration tied to specific operational milestones.
- Profile Integration: Scale Bio functions as a specialized single-cell genomics technology entity. This acquisition directly enriched the parent company’s portfolio with the highly advanced QuantumScale Single Cell RNA and Methylation kits.
Other Investments (Including Minority / Portfolio Holdings)
While the firm primarily focuses on whole acquisitions and internal development, it selectively invests heavily in intellectual property through asset purchases to secure critical technological frameworks.
Centrillion Technologies IP Assets
In January 2023, the enterprise entered into an agreement to aggressively acquire intangible and other critical assets from Centrillion Technologies, Inc. and Centrillion Technology Holdings Corp.
- Ownership Nature: Strategic intellectual property asset purchase, rather than an equity holding.
- Financial Scope: The initial outlay was $10.0 million, and through December 31, 2025, the enterprise has paid an aggregate of $41.3 million toward technology development milestones associated with this intellectual property.
- Profile Context: This investment is fundamentally designed to expand the firm’s foundational patent moats and secure exclusive access to next-generation genomic technologies essential for future product iterations.
Physical Properties
The enterprise operates a highly specialized, globally distributed physical infrastructure network explicitly designed to support intensive research, development, and high-precision manufacturing.
- Pleasanton, California Campus: The organization’s nerve center. The company owns approximately 148,000 square feet of customized facility space here and leases an additional 300,000 square feet (with lease expirations ranging from September 2029 to June 2033). This complex houses the global corporate headquarters, the majority of the research and development scientists, quality assurance teams, and vast consumable manufacturing operations.
- Singapore Hub: A state-of-the-art manufacturing and distribution center strategically positioned to support the burgeoning Asia-Pacific and EMEA markets.
- Taiwan Facility: A dedicated manufacturing center ensuring supply chain redundancy and specialized component production capabilities within the robust Asian technology ecosystem.
Founders
The scientific and commercial foundation of the enterprise was laid by its founding team, with Serge Saxonov standing at the forefront. Currently serving as the Chief Executive Officer, Saxonov has maintained a steadfast focus on constructing multidisciplinary teams that bridge the gap between chemistry, software, and hardware to answer some of biology’s most daunting questions.
Parent
10x Genomics, Inc. acts as the ultimate parent company within its corporate structure. It does not operate under any higher-level holding company or corporate parent, ensuring that its strategic direction remains entirely independent and fully focused on the life sciences research tools market.
Investments and Capital Expenditure Plans
The firm allocates immense financial resources to safeguard its technological lead, scaling its operational capacity, and fortifying its intellectual property.
- R&D Commitment: In 2025 alone, the company poured $238.6 million into research and development expenses, emphasizing the development of new solutions, instrument firmware sophistication, and holistic software workflows.
- Capital Expenditures: The organization spent $5.9 million in 2025 explicitly on property and equipment purchases to maintain its laboratory and manufacturing footprint.
- Commercial Investments: A massive strategic priority involves recruiting, training, and expanding specialized commercial teams—specifically those dedicated to pushing the Xenium platform into the market.
- Clinical and Diagnostics Pipeline: A prominent future investment vector focuses aggressively on adapting existing research-use-only (RUO) products to pass stringent FDA requirements, thus permitting entry into highly lucrative clinical and diagnostic markets.
Shareholding Pattern
The corporate voting structure is meticulously designed to concentrate control in the hands of the company’s early stakeholders, shielding long-term scientific strategy from short-term public market pressures.
- Class A Common Stock: The company reported 117,673,382 shares of Class A common stock outstanding. Each share within this class is entitled to one standard vote.
- Class B Common Stock: The company holds 10,078,872 shares of Class B common stock outstanding. Crucially, each Class B share carries the extraordinary weight of ten votes per share, establishing a powerful multi-class voting dynamic.
Future Strategy
The organization’s strategic horizon is defined by aggressive expansion beyond the traditional academic sphere and deep into applied medicine and data simplification.
- Clinical Ascension: The leadership team is actively mapping a strategy to penetrate the clinical and diagnostic markets. This will require subjecting their technologies to rigorous FDA oversight to enable their use in actual disease diagnosis and treatment workflows.
- Software Democratization: As their instruments produce increasingly massive and complex datasets, the firm views intuitive software as critical for adoption. They intend to expand their software ecosystem (including Cell Ranger, Loupe Browser, and Xenium Explorer) through proprietary development and strategic partnerships.
Key Strengths
The enterprise leverages highly defensible competitive advantages that insulate its market position.
- Deep Cross-Disciplinary Integration: Unlike competitors who focus solely on hardware or chemistry, the firm houses elite talent across chemistry, biology, hardware, computational biology, and software engineering, allowing them to build perfectly harmonized end-to-end ecosystems.
- Fiercely Defended Intellectual Property: The company possesses a robust patent portfolio and has proven its willingness and financial capacity to relentlessly litigate against infringement. The massive 2025 settlements with Vizgen and Bruker demonstrate the strength and enforceability of their IP moats.
- Highly Profitable Razor-and-Blade Model: By driving initial instrument placements, the company creates a captive audience that continuously consumes high-margin chemical reagents and microfluidic chips, ensuring highly predictable and recurring revenue streams.
Key Challenges and Risks
Despite its dominant market posture, the company is exposed to intense external vulnerabilities.
- Extreme Reliance on Government Funding: A massive portion of their academic customer base relies entirely on grants from entities like the NIH. Any governmental budgetary constraints, delays, or political reprioritizations could instantly evaporate customer purchasing power.
- Geopolitical and Trade Volatility: The firm is highly dependent on the Asia-Pacific region for sales and Taiwan/Singapore for manufacturing. Deteriorating US-China relations, new tariffs, or military disruptions in the Taiwan Strait could shatter supply chains or lock the firm out of essential markets.
- Single-Source Supplier Bottlenecks: The complex chemistry required for their consumables relies on highly specialized raw materials, such as specific oligonucleotides and enzymes. The company relies on single-source or sole-source suppliers for several critical components, meaning a disruption at a single third-party factory could halt global production.
Conclusion and Strategic Outlook
10x Genomics, Inc. has cemented itself as an undisputed pioneer in the realms of single-cell and spatial biology. The 2025 fiscal year underscored the company’s financial resilience, characterized by massive strides toward profitability—shrinking net losses dramatically from $182.6 million down to $43.5 million while growing top-line revenue to $642.8 million. The strategic acquisition of Scale Bio, combined with the incredibly successful defense of its intellectual property against major competitors like Vizgen and Bruker, has fortified the company’s technological and legal boundaries. Moving forward, the firm’s capacity to democratize massive biological data through intuitive software and its ambitious foray into clinical diagnostic markets will ultimately dictate its ability to transition from a pure research tool provider into a foundational pillar of modern healthcare.
FAQ
What is the core technology of 10x Genomics?
10x Genomics specializes in integrated solutions for interrogating biological systems at single-cell and spatial resolutions. Their core platforms—Chromium, Visium, and Xenium—combine advanced microfluidic and optical instruments, proprietary chemistry consumables, and complex software to allow researchers to map biology at a level of detail previously thought impossible.
How much revenue did 10x Genomics generate in 2025?
The company reported a total revenue of $642.8 million for the fiscal year ended December 31, 2025, which represents an increase from the $610.8 million generated in 2024.
What drives the majority of the company’s revenue?
The vast majority of the company’s revenue is generated through its Consumables division, which brought in $526.0 million in 2025. Customers who purchase instruments must continually buy these high-margin chemical and biological reagents to perform their experiments.
Did 10x Genomics acquire any companies recently?
Yes, in August 2025, the company acquired Scale Biosciences, Inc. (Scale Bio), a single-cell genomics technology firm. The transaction involved a $9.2 million cash payment and $13.5 million in Class A common stock, successfully integrating the QuantumScale Single Cell kits into the 10x product family.
How is the voting power structured among shareholders?
The company utilizes a multi-class stock structure. Class A common stock carries one vote per share, while Class B common stock carries ten votes per share. This structure purposefully concentrates voting control among the historical stakeholders and founders holding the Class B shares.
What are the primary risks facing the business?
Key risks include a heavy reliance on academic and government funding (like NIH grants) for customer purchasing power, geopolitical tensions and tariffs affecting the Chinese market and Taiwanese manufacturing, and a dangerous dependency on single-source suppliers for critical chemical reagents and instrument components.
Official Site: https://www.10xgenomics.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
